# The $400 Billion Middleman
Hook: Between you and your medication, there's a company you've probably never heard of. It doesn't make the drug. It doesn't sell the drug. It doesn't prescribe the drug. But it decides what you pay for it.
What Is a PBM?
A pharmacy benefit manager is supposed to negotiate lower drug prices on behalf of insurance companies and employers. In theory, PBMs use their market power to get discounts from manufacturers, passing savings on to patients and insurers.
In practice, the three largest PBMs — CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth) — control approximately 80% of the prescription drug market in the United States. They are owned by the same parent companies that own the insurance plans and, in some cases, the pharmacies.
How the Money Flows
Here's the chain from manufacturer to patient:
Manufacturer → sets a list price (WAC) PBM → negotiates a "rebate" off the list price Insurer → pays the PBM's negotiated price Pharmacy → dispenses the drug at the insurer's approved copay Patient → pays their copay (often based on the *list* price, not the rebated price)
The critical insight: PBMs are incentivized to keep list prices high. Their rebates are typically calculated as a percentage of the list price. A higher list price means a bigger rebate, which means more money flowing through the PBM. The patient's copay, meanwhile, is often calculated from that same inflated list price.
Vertical Integration: The Real Problem
In 2018, CVS Health acquired Aetna for $69 billion. The result: CVS now owns the insurance company (Aetna), the PBM (CVS Caremark), and the pharmacy (CVS Pharmacy). Your insurer, your drug negotiator, and your drug seller are the same company.
The FTC launched an investigation into PBM practices in 2022 and published interim findings that confirmed what patients already knew: the system is designed to maximize PBM revenue, not minimize patient costs.
The Key Insight
This is rent-seeking. PBMs don't create the drugs. They don't improve the drugs. They don't deliver care. They sit between the people who make drugs and the people who need drugs, and they extract profit from both directions. The system persists because it's complex enough that most people don't know who to blame — and the PBMs spend hundreds of millions lobbying to keep it that way.
Understanding this single concept — that the complexity is a feature, not a bug — changes how you see every drug pricing debate.